Overview
- Doximity reported Wednesday that revenue rose 5% to $145.4 million and beat estimates, but adjusted EPS fell to $0.26 and missed forecasts.
- The company guided fiscal 2027 revenue to $664–$676 million and Q1 to $151–$152 million, both below Wall Street views, and it projected about a 49% adjusted EBITDA margin due to higher AI compute costs.
- Executives said short-term demand in the healthcare professional digital pharma ad market is weak, which reduces visibility on near-term growth.
- Doximity is leaning into clinical AI, reporting 800,000 active prescribers in Q4 with nearly half using its AI tools, and it announced an integration with value-based care firm Aledade.
- Following Thursday’s selloff in premarket trading, shares fell roughly 20–24% to new lows as Jefferies, Wells Fargo, and KeyBanc cut ratings and targets.